Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical ...